The UK and US have forged a major commercial pact that will preserve no duties on British drug exports being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that import taxes on these key goods will stay at nothing for a timeframe of the next three years.
This development comes after earlier warnings to hike tariffs on patented drug products, with figures discussed as high as double the cost.
"This agreement with the Britain reinforces the global environment for new treatments and introduces long-overdue balance to transatlantic medicine commerce," a statement noted.
Trade Significance
Drugs represent one of the Britain's biggest goods shipped to the America, which is by far the largest market for large companies like GSK and AstraZeneca.
Export figures show that in the 12 months leading up to September, the UK exported drugs worth £11.1bn to the US. This amount represented a significant portion of British export trade in that period.
"This guarantee protects work, boosts funding and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Detailed British Pledges
The agreement entails several specific pledges from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to double total public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be restricted at fifteen percent. Previously, repayments exceeded 20%.
Recent Tensions
The deal follows a long-running dispute between the sector and the UK government over spending levels and NHS adoption.
The disagreement were heightened by assertions that American patients were paying several times more for the identical medicines than patients in the UK and Europe.
In recent months, several major drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been pledged toward American operations.
A senior figure stated that the NHS had to spend more on medicines, noting that its expenditure on drugs had declined as a proportion of its overall budget over the previous ten-year period.
